P-1937. Does Microbiological Clearance Impact Outcomes in Patients Contracting Candida auris?

Read full text
Authors: Hafsa Khan Tareen, Samavia Mehmood, Joveria Qais Farooqi, Sadaf Zaka, Kauser Jabeen
Cited by: 0

Abstract

Abstract Background The CDC reported an increase in C. auris cases from 44% to 95% between 2019-2021. An estimated 41% of Candida auris isolates are already resistant to >2 antifungals. Since its first report in 2014, recent data on the trend of C. auris fungemia from Pakistan is not readily available. This data assessed changes in epidemiology, antifungal resistance, and clinical outcomes of C. auris fungemia.Table:Multivariable analysis with adjusted Odds Ratios (aOR) Methods Retrospective cross-sectional study was conducted at Aga Khan University Hospital, Karachi, from 2017 to 2024. Clinical outcomes included mortality, length of hospital and ICU stay, and microbiological failure (defined as persistent positive blood cultures beyond seven days of antifungal therapy). Data on clinical characteristics included comorbidities, immunosuppression, prior antimicrobial exposure, MDR co-infections, and surgical interventions. Results 155 patients were included, with a median age of 54.0 years (IQR: 26.0–70.0), 60.6% of which were males, median length of hospital stay was 13.0 days (IQR: 4.0–24.0), and ICU stay was 17.5 days (IQR: 5.0–30.0) with 32.9% requiring mechanical ventilation. Median antifungal duration was 7.0 days (IQR: 5.0–12.0). The MIC50 and MIC90 was 64.0 µg/mL, 256µg/mL for fluconazole; 1.0 µg/mL,1.0 µg/mL for amphotericin; and 0.12 µg/mL, 0.25 µg/mL for anidulafungin. Resistance to fluconazole was noted in 94.3% of the tested isolates, while all tested isolates remained sensitive to amphotericin and anidulafungin. Most patients stayed in the hospital for a duration of 1–2 weeks (38.7%, n=60). Hypertension (46.5%, n=72) and diabetes mellitus (40.0%, n=62) were the most frequently reported comorbidities. Over one-third (36.8%) had ≥2 positive blood cultures. Prior antibiotic and antifungal exposure were 94.2% and 29.0%, respectively. Crude mortality was 41.3% (n=64). Conclusion While earlier studies have compared mortality between C. auris and non-C. auris candidemia as a newly emerging disease, we have tried to explore the factors associated with death in C. auris candidemia patients. Lack of microbiologic clearance had a fourfold increased risk of inpatient mortality (aOR: 3.97). Older age (aOR: 5.7), malignancy (aOR: 5.07), and invasive mechanical ventilation (aOR: 6.58) emerged as strong independent predictors of mortality. Disclosures All Authors: No reported disclosures

Fields of Study & Subjects

Antifungal resistance and susceptibility Fungal Infections and Studies Ocular Infections and Treatments

Publication details

Journal / source
Open Forum Infectious Diseases
Volume
13
Issue
Supplement_1
Publication date
1 January 2026
Language
EN